Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2025 08:45 ET | Source: GRI Bio, Inc.

GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

The Independent Data Monitoring Committee (IDMC) has recommended to continue the study as planned as there are no safety concerns seen in the data reviewed Continued momentum with completed patient...
April 01, 2025 09:00 ET | Source: GRI Bio, Inc.

GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

The Independent Data Monitoring Committee (IDMC) has recommended to continue study as planned as there are no safety concerns seen in the data reviewed Interim results demonstrate GRI-0621 to be safe...
February 03, 2025 07:05 ET | Source: uniQure Inc.

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

~ Independent Data Monitoring Committee recommends proceeding with dosing of second cohort after planned safety assessment ~ ~ Company expects to initiate enrollment of second dose cohort in the...
January 30, 2025 07:37 ET | Source: uniQure Inc.

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

~ Independent Data Monitoring Committee Recommends Proceeding with Dose Escalation After Planned Safety Assessment of First Dose Cohort ~ ~ Company Expects to Initiate Enrollment of Second Dose...
April 15, 2020 08:30 ET | Source: Celsion CORP

Celsion Reports that Sufficient Events Have Been Reached for the Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer

Independent Data Monitoring Committee is Expected to Meet in July 2020 to Evaluate Overall Survival Data LAWRENCEVILLE, N.J., April 15, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:...
November 14, 2019 16:05 ET | Source: Celsion CORP

Celsion Corporation Reports Third Quarter 2019 Financial Results and Provides Business Update

Independent Data Monitoring Committee (iDMC) Unanimously Recommends Continuation of Phase III OPTIMA Study at First Pre-Planned Efficacy AnalysisIndependent Data Safety Monitoring Board (DSMB)...
August 14, 2019 16:30 ET | Source: Celsion CORP

Celsion Corporation Reports Second Quarter 2019 Financial Results and Provides Business Update

First Pre-Planned Efficacy Analysis of the Phase III OPTIMA Study Planned for Mid-October Strong Balance Sheet Plus the Non-Dilutive Sale of $4 Million of New Jersey State Net Operating...
August 05, 2019 09:00 ET | Source: Celsion CORP

Celsion Announces Data Lock for First Interim Analysis in OPTIMA Phase III Study of ThermoDox® in Primary Liver Cancer

Independent Data Monitoring Committee to Meet in October to Evaluate Interim Trial Data LAWRENCEVILLE, N.J., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology...
July 26, 2019 01:00 ET | Source: ObsEva SA

ObsEva SA Reports Positive Feedback from Independent Data Monitoring Committee for PROLONG Part B with OBE022

Geneva, Switzerland and Boston, MA – July 26, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...